At a time when the 'zillion dollar' global pharmaceutical industry simply abandons, for business reasons, research in search of new, more efficient antibiotics potent, the action of so-called superbugs, already resistant to traditional medicines, accounts for the increase, from 700 thousand to 1.2 million, in the number of deaths in the planet.
The alert was launched by the World Health Organization (WHO), through the report entitled “Encouraging the Development of New Antibacterial Treatments 2023”. In general, such microorganisms cause apparently common, but no less deadly, illnesses, such as pneumonia, urinary tract and bloodstream infections, as well as tachycardia, fever, swelling and even multiple heart failure. organs.
see more
Historic! Archaeologists make FASCINATING discovery on the outskirts of…
Winter 2023 is among the warmest since 1961, according to…
The sad observation is that, currently, the volume of ongoing research for new antibiotics has shown itself to be 'insufficient' to 'face' the overwhelming growth of resistance antibacterial. Instead, most antibiotics available on the market are mere generic variations of drugs developed in the distant 1980s.
But what is really worrying is knowing that the majority of the 77 new drugs currently in clinical development in the world, derives from a class of already existing antibiotics, with a high probability of not even reaching the Marketplace.
In perspective, taking into account that bacteria become resistant earlier and earlier, more Medicines quickly become obsolete and are then discarded by the industry pharmaceutical. According to the report, “there is no viable market for new antibiotics. The financial return does not cover the costs of its development, production and distribution”, concluding that “the main pharmaceutical companies have retreated in the development of antibiotics”.
To get an idea of the degree of humanity's exposure to new diseases, giants in the sector, such as Novartis, AstraZeneca, Sanofi, Allergan and Medicines, a decade ago, ended their research antibacterial.
In the researchers' assessment, the private sector's preference falls on “more profitable areas, such as oncology”, which consumed research worth US$ 26.5 billion, compared to US$ 1.6 billion for research antibacterial.
As a hope, it is worth hoping that the public sector – which, in principle, does not aim for profit – takes on the role of financing new research. While companies invest US$1.8 billion per year in research in this direction, governments from the G7 – group of the richest countries in the world – began to invest an equivalent amount, following a commitment signed in 2022. The expectation is that at least four new antibiotics will be launched by 2030.
By reiterating the need for strong state investment to “stop the spread of superbugs” in the country, the executive president of Sindusfarma (Sindicato da Indústria de Produtos Pharmacists), Nelson Mussolini, celebrated the relaunch of Geceis, the Health Economic and Industrial Complex, which intends to produce in Brazil 70% of the raw material for new medicines.
